Fenugreek extract topical gel to treat scally skin disease

Clinical and biochemical impact of fenugreek (trigonella foenum graecum) seeds on Insulin resistance in psoriatic patients visiting tertiary care hospitals of Rawalpindi

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

REBEC

Registry ID

RBR-6srbb6p

Enrollment

Unknown

Registered

2025-10-30

Start date

2025-10-04

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

The intervention involves topical application of a 5% fenugreek (Trigonella foenum-graecum) seed extract gel for the management of mild to moderate psoriasis. A total of 200 participants will be enrol

Eligibility

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria, Psoriatic patients;Age between 18 and 65 years; males and females; both diabetic and non-diabetic psoriatic patients

Exclusion criteria

Exclusion criteria: History of alcohol abuse; prior or current use of hepatotoxic medications; any known liver disease; Individuals with clinical evidence of acute hepatitis or positive hepatitis B surface antigen (HBsAg); pregnant or lactating women; individuals with known allergy to fenugreek

Design outcomes

Primary

Measure	Time frame
The study is expected to show that the 5% fenugreek (Trigonella foenum-graecum) topical gel reduces psoriatic lesion area by approximately 40–60% after 8 weeks of treatment, with a marked decrease in redness, scaling, and itching. It is anticipated that over 70% of participants will experience at least a moderate improvement in their Psoriasis Area and Severity Index (PASI) score, and 80% will report enhanced comfort and quality of life. The topical formulation is expected to demonstrate excellent skin tolerance, with no serious local or systemic adverse reactions observed during the treatment period	—

Measure

Time frame

The study is expected to show that the 5% fenugreek (Trigonella foenum-graecum) topical gel reduces psoriatic lesion area by approximately 40–60% after 8 weeks of treatment, with a marked decrease in redness, scaling, and itching. It is anticipated that over 70% of participants will experience at least a moderate improvement in their Psoriasis Area and Severity Index (PASI) score, and 80% will report enhanced comfort and quality of life. The topical formulation is expected to demonstrate excellent skin tolerance, with no serious local or systemic adverse reactions observed during the treatment period

—

Secondary

Measure	Time frame
No secondary outcome.	—

Countries

Pakistan

Contacts

Public ContactBushra Bilal

National University of Medical Sciences Rawalpindi Pakistan

bushra.bilal@numspak.edu.pk+923005391081

Outcome results

None listed

Source: REBEC (via WHO ICTRP)